Aqemia

Aqemia is an Ile-de-France-based company founded in 2019 using in silico machine learning methods to discover and develop new drugs. The Aqemia generative artificial intelligence (AI) creates molecular compounds and predicts the molecules' interactions as pharmaceutical compounds within specific patients. Initially, Aqemia was developed at École Normale Supérieure Paris. However, it became a spin-off company in 2019 when it was formally founded by Maximilien Levesque, the current CEO, and Emmanuelle Martiano, the current COO.

École Normale Supérieure Paris is considered a selective and prestigious graduate school located in Paris, France. Maximilien Leveque was a university professor teaching quantum mechanics and theoretical chemistry from 2014 to 2017 before teaching machine learning from 2017 to 2020. During Leveque's career at École Normale Supérieure, he was a research group leader (2014-2020), where he developed the technology for Aqemia.